

Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

Ryo Takahashi¹, Haruhiko Hirata¹, Isao Tachibana¹, Eku Shimosegawa², Atsuo Inoue², Izumi Nagatomo¹, Yoshito Takeda¹, Hiroshi Kida¹, Sho Goya¹, Takashi Kijima¹, Mitsuhiro Yoshida¹, Toru Kumagai¹, Atsushi Kumanogoh¹, Meinoshin Okumura³, Jun Hatazawa², and Ichiro Kawase⁴

Abstract

Purpose: Positron emission tomography (PET) with [¹⁸F]fluorodeoxyglucose (FDG) is increasingly used in early assessment of tumor response after chemotherapy. We investigated whether a change in [¹⁸F]FDG uptake at 2 days of gefitinib treatment predicts outcome in patients with lung adenocarcinoma.

Experimental Design: Twenty patients were enrolled. [¹⁸F]FDG-PET/computed tomographic (CT) scan was carried out before and 2 days after gefitinib treatment. Maximum standardized uptake values (SUV) were measured, and post-gefitinib percentage changes in SUV were calculated. Early metabolic response (SUV decline < -25%) was compared with morphologic response evaluated by CT scan and with progression-free survival (PFS).

Results: At 2 days of gefitinib treatment, 10 patients (50%) showed metabolic response, 8 had metabolic stable disease, and 2 had progressive metabolic disease. Percentage changes of SUV at 2 days were correlated with those of tumor size in CT at 1 month ($R^2 = 0.496$; $P = 0.0008$). *EGFR* gene was assessable in 15 patients, and of 12 patients with *EGFR* mutations, 8 showed metabolic response at 2 days and 6 showed morphologic response at 1 month. None of 3 patients with wild-type *EGFR* showed metabolic or morphologic response. Metabolic response at 2 days was not statistically associated with PFS ($P = 0.095$), but when a cutoff value of -20% in SUV decline was used, metabolic responders had longer PFS ($P < 0.0001$).

Conclusion: Early assessment of [¹⁸F]FDG tumor uptake with PET at 2 days of gefitinib treatment could be useful to predict clinical outcome earlier than conventional CT evaluation in patients with lung adenocarcinoma. *Clin Cancer Res*; 18(1); 220-8. ©2011 AACR.

Introduction

Treatment of non-small cell lung cancer (NSCLC) has made remarkable progress in the last decade; the epidermal growth factor receptor (EGFR), which is expressed in more than 60% of patients with metastatic NSCLC and correlates

with poor prognosis (1), has emerged as an important molecular target for advanced or recurrent NSCLC. Reversible EGFR tyrosine kinase inhibitors (TKI), gefitinib and erlotinib, were found to have antitumor activities in second- or third-line therapy (2-4). Objective responses with these agents were limited to a subpopulation of patients, which included never-smokers, women, East Asians, and patients with adenocarcinoma histology (4, 5). It was later shown that most of these responders harbor specific mutations or increased copy number in the gene encoding EGFR that enhances tyrosine kinase activity (6, 7). Indeed, gefitinib as first-line and single-agent therapy improved progression-free survival (PFS) of patients with NSCLC with the *EGFR* mutations when compared with standard chemotherapy (8-10). Although these genetic markers may be used to predict therapeutic response, they do not guarantee successful treatment as a portion of marker-positive patients did not respond to the EGFR TKIs, whereas a portion of marker-negative patients did respond (11). Moreover, a secondary mutation in the *EGFR* gene or amplification of *c-Met* negates the sensitizing effect, leading to acquired

Authors' Affiliations: Departments of ¹Respiratory Medicine, Allergy and Rheumatic Diseases, ²Nuclear Medicine, and ³General Thoracic Surgery, Osaka University Graduate School of Medicine; and ⁴Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

R. Takahashi and H. Hirata contributed equally to the work as the first authors.

Corresponding Author: Isao Tachibana, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-3833; Fax: 81-6-6879-3839; E-mail: itachi02@imed3.med.osaka-u.ac.jp

doi: 10.1158/1078-0432.CCR-11-0868

©2011 American Association for Cancer Research.

Translational Relevance

It remains difficult to accurately predict clinical benefit of gefitinib in patients with non-small cell lung cancer (NSCLC). A recent basic study using a mouse model has shown that gefitinib induces a decrease of fluorodeoxyglucose (FDG) uptake within 48 hours in sensitive NSCLC tumors. We conducted a pilot study to validate the use of early FDG-positron emission tomography (PET) in clinical settings. Assessment of FDG uptake only after 2 days of gefitinib treatment was able to predict tumor response and progression-free survival. This early assessment could help to identify patients who will benefit from gefitinib therapy while allowing for rapid initiation of alternative strategies and minimizing critical adverse effects such as interstitial lung disease when gefitinib is ineffective.

resistance to the EGFR TKIs (12). Thus, it appears difficult to predict clinical benefit accurately only with these genetic biomarkers.

Positron emission tomography (PET) with [¹⁸F]fluorodeoxyglucose (FDG) plays a role in the diagnosis and staging of lung cancer. It is based on high glucose metabolism in tumor cells that have an increased level of glucose transport protein expression and hexokinase activity. In addition to diagnosis and staging, [¹⁸F]FDG-PET is increasingly used to assess tumor response and to predict outcome. A decrease in FDG uptake in sensitive tumor cells can be detected earlier than structural changes occur (13). This is the case especially in tumors treated with molecularly targeted drugs rather than with cytotoxic agents. In gastrointestinal stromal tumors (GIST), FDG-PET has been shown to be highly sensitive in detecting early response to imatinib mesylate, a small molecule that inhibits c-KIT. Decreases in FDG uptake were observed after 1 week of treatment, whereas volume responses evaluated on computed tomographic (CT) scan were small and developed more slowly (14, 15). In NSCLC, it has remained unknown that how EGFR TKIs downregulate FDG uptake after initiation of treatment in sensitive tumors. Recently, using a mouse xenograft model, Su and colleagues showed rapid decreases of tumor FDG uptake in sensitive xenografts within 48 hours of gefitinib treatment (16). They also found a decline in FDG uptake 24 to 48 hours before inhibition of proliferation and induction of apoptosis in a gefitinib-sensitive NSCLC cell line. A more recent preliminary study, which evaluated [¹⁸F]FDG-PET in 5 patients with advanced NSCLC treated with gefitinib, suggested that FDG-PET may be able to predict the response. Patients exhibiting a partial response on CT evaluation already showed a mean of 61% decrease in FDG uptake at 2 days of therapy (17). Thus, further prospective studies are needed to confirm that [¹⁸F]FDG-PET provides an early sensitive marker of the effectiveness of gefitinib in patients with NSCLC.

In the present study, we prospectively evaluated FDG-PET only after 2 days of gefitinib treatment in patients with lung adenocarcinoma to predict response and outcome. We used a combined PET/CT scan to provide correct anatomic registration of PET data.

Materials and Methods

Patients

Twenty patients with lung adenocarcinoma who received gefitinib treatment were enrolled from November 2007 to November 2009. Diagnosis was made either histologically or cytologically. Gefitinib at a dose of 250 mg once a day was administered orally 30 minutes after breakfast as the first EGFR tyrosine kinase inhibition therapy, until disease progression, unacceptable toxicity, or patient refusal. Eligibility criteria included an age of 20 years or more, unresectable stage or relapse after surgery, measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The study protocol was approved by the Institutional Review Board of Osaka University Hospital, Osaka, Japan, and written informed consent was obtained from all patients.

EGFR mutation analysis

Mutation analysis of *EGFR* in exons 18, 19, 20, and 21 was conducted using biopsy specimens obtained at diagnosis. Genomic DNA was extracted and analyzed by peptide nucleic acid-locked nucleic acid PCR (PNA-LNA PCR) clamp method manufactured in Mitsubishi Chemical Medience Co., as previously described (18).

FDG-PET/CT

[¹⁸F]FDG-PET/CT was conducted before (at baseline), 2 days, and 1 month after gefitinib administration using a GEMINI GXL scanner (Philips Medical Systems). Baseline scan was done within 14 days prior to the treatment. All patients were fasted for at least 4 hours before scanning. Their serum glucose levels were less than 150 mg/dL before FDG injection. One hour after the injection of 3.7 MBq/kg [¹⁸F]FDG, patients were scanned from the head to the thigh. We calculated accurate [¹⁸F]FDG uptake time for each patient and confirmed that there was no significant difference between any metabolic responders and nonresponders. After a 50-mAs low-dose CT scan for attenuation correction, emission scan was obtained in a 3-dimensional acquisition mode at 11 to 12 bed positions with 2 min/bed speed. In-plane and axial field of view of the scanner were 576 mm and 180 mm, respectively. In-plane spatial resolution was 6.31 mm full width at half maximum (FWHM) at the center with 144 × 144 pixel size (4 × 4 × 4 mm³/pixel). Images were reconstructed by line-of-response row-action maximum likelihood algorithm (LOR-RAMLA) method. After acquisition of the PET images, a diagnostic chest CT was conducted by a 16-row multidetector scanner in a helical mode with 120 kV of the tube voltage and 200 mAs of the effective tube current. CT gantry rotation time was 0.5 seconds with an axial field of view of 600 mm,

producing 5-mm thick slices with a 512×512 matrix. Regions of interest were placed over the highest accumulation area, corresponding to tumor sites on the PET images. The maximal standardized uptake value (SUV) was determined as previously described (19).

Response assessment and follow-up

Among measurable lesions according to the Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST 1.0; ref. 20) in fused mode of dual modality PET/CT, up to 5 lesions in order of [^{18}F]FDG uptake level were defined as target lesion on the baseline scan. [^{18}F]FDG uptake was evaluated as the SUV of the target lesions (21). The lowest SUV of target lesions was 1.6, which was still higher than the background (Table 1). On PET/CT at 2 days and 1 month of gefitinib administration, percentage changes in the sum of these SUVs of the target metabolic lesions were determined on the basis of the baseline scan, and time point metabolic response was defined according to the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET study group (22). Complete metabolic response (CMR) was achieved when SUVs of all lesions were decreased to uptake equivalent to background. Partial metabolic response (PMR) was defined as percentage change of the sum of SUVs ($\Delta\text{SUV}\%$) $< -25\%$, stable metabolic disease (SMD) was $-25\% \leq \Delta\text{SUV}\% < +25\%$, and progressive metabolic disease (PMD) was defined as $+25\% \leq \Delta\text{SUV}\%$ or when the extent of [^{18}F]FDG increased greater than 20% in the longest dimension or when new [^{18}F]FDG uptake appeared in metastatic lesions. In analysis of PFS, a cutoff value of -20% , instead of -25% , was also used to separate responders from nonresponders. Changes in tumor size of the same target lesions as [^{18}F]FDG uptake analysis and nontarget lesions were quantified on CT images from PET/CT data at 1 month by 2 of the authors blinded to the PET data, and time point overall response was classified according to RECIST 1.0. Percentage changes in the sum of the longest dimension ($\Delta\text{CTsize}\%$) of the target lesions were also determined and compared with $\Delta\text{SUV}\%$. On CT images at 2 days of gefitinib administration, all patients were with stable disease. Chest CT or radiograph was repeated every 4 weeks until disease progression, which was determined by RECIST 1.0. The overall responses classified at 1 month were not confirmed by the repeat assessments in this study.

Statistical analysis


Data were analyzed using JMP statistical discovery software version 8.0.2 (SAS Institute). Correlation between $\Delta\text{SUV}\%$ at 2 days and $\Delta\text{CTsize}\%$ at 1 month was evaluated by Fisher ANOVA. Agreement between the EORTC recommendations-based metabolic response at 2 days and RECIST-based morphologic overall response at 1 month was evaluated using kappa statistic (23). PFS was measured from the first administration of gefitinib to documented progression or death of any cause. Overall survival (OS) was from the first administration of gefitinib to death of any cause. PFS and OS were estimated using the Kaplan–Meier

Table 1. Patient characteristics at baseline

Characteristic	N
Total no. of patients	20
Sex	
Male	5
Female	15
Age, y	
Median	69
Range	58–83
ECOG performance status	
0	10
1	10
Smoking history	
Never	15
Ever	5
Clinical stage	
IIIA	2
IIIB	3
IV	15
No. of prior chemotherapy	
0	10
1	6
2	2
3	1
4	1
EGFR mutation status	
Exon 19	6
Exon 21	5
Exon 18	1
Wild-type	3
Not determined	1
Not tested	4
Baseline study	
No. of target lesions	
Median	2.5
Range	1–5
SUV of target lesions	
Median	5.9
Range	1.6–13.0
Size of target lesions, cm	
Median	2.0
Range	1.2–7.7

method and compared by the 2-sided log-rank test (24). HRs were calculated using the Cox proportional hazards model. In multivariate Cox model analysis, metabolic response at 2 days and morphologic response at 1 month, significance of which was $P < 0.15$ in univariate analysis, were chosen as variable in addition to smoking history, which was previously shown to be a prognostic factor for patients with gefitinib-treated NSCLC (5). EGFR mutation status was not included because it was not determined or tested in 5 patients, and the number of patients with wild-type EGFR was only 3.

Figure 1. Pre- and posttreatment images of FDG-PET/CT scans of a 67-year-old female (A, D, and G) and a 75-year-old female (B, E, and H), who achieved partial response at 1 month (G and H, respectively), and an 81-year-old male (C, F, and I), who had progressive disease at 1 month (I) as assessed by RECIST 1.0. The first 2 patients already showed partial metabolic response at 2 days (D and E), and the third patient was assessed with progressive metabolic disease at 2 days (F).



Results

Patient characteristics

A total of 20 patients (15 females and 5 males) were enrolled in this study, underwent PET/CT for baseline assessment, and received gefitinib treatment. Nineteen were patients with adenocarcinoma and one with adenosquamous carcinoma. Fifteen patients (75%) had clinical stage IV disease. Five patients at clinical stage III were not treated with surgery or radiation due to the presence of malignant pleural effusion and complicating diseases. Ten were previously untreated and 10 had been treated with 1 to 4 chemotherapy regimens. Detailed patient characteristics are shown in Table 1. Median time between the baseline PET/CT and the start of gefitinib treatment was 4 days (range, 0–13 days), and no chemotherapy was administered during this period. A 77-year-old male patient did not complete PET/CT at 1 month because ground-glass opacity appeared on chest radiograph and gefitinib administration was discontinued at 6 days of treatment; this patient was excluded from later assessment. In all the other patients, gefitinib was continued to documented disease progression, and none of them received additional treatment without documented progression. Overall, early response at 2 days was assessed in 20 patients, and late response assessment at 1 month and PFS analysis were conducted in 19 patients.

Comparative analysis of metabolic and morphologic responses

Metabolic responses could be detected only at 2 days of treatment, when morphologic responses were still unrecognizable. Representative PET/CT images of responders and nonresponders during gefitinib treatment were shown in Fig.

1. Median percentage change of the sum of SUVs (Δ SUV%) of target lesions was -23% . Sixteen patients experienced Δ SUV% reduction ranging from -2% to -52% (Fig. 2A). No patient achieved a complete metabolic response (SUVs of all lesions equivalent to background) and 10 (50%) patients achieved a partial metabolic response (Δ SUV% $< -25\%$). Four patients experienced an increase of Δ SUV% ranging from $+6\%$ to $+36\%$ and 2 of these were assessed with progressive metabolic disease ($+25\% \leq \Delta$ SUV%). These changes of target lesions in SUV at 2 days of treatment were compared with those in tumor size (Δ CTsize%) at 1 month of treatment, which was quantified on CT images, and there was a strong correlation ($R^2 = 0.496$; $P = 0.0008$) as shown in Fig. 2B. There was also a moderate agreement ($\kappa = 0.566$) between metabolic responses at 2 days based on the EORTC recommendations and morphologic overall responses at 1 month according to RECIST 1.0 (Fig. 2C). Of 10 metabolic responders at 2 days, 8 patients were morphologic responders and 2 were with stable disease by RECIST 1.0 at 1 month. Of 7 patients with stable metabolic disease ($-25\% \leq \Delta$ SUV% $< +25\%$) at 2 days, 5 patients were assessed with morphologically stable disease and 2 had progressive disease by RECIST 1.0 at 1 month. Median PFS of patients with partial metabolic response, stable metabolic disease, and progressive metabolic disease was 290, 48, and 39 days, respectively. Median PFS of patients with morphologic partial response, stable disease, and progressive disease was 267, 100, and 29 days, respectively.

EGFR mutation

Biopsy samples from 5 patients were not suitable for molecular analysis. Mutation of *EGFR* gene was assessable in 15 patients and 12 were *EGFR* mutation positive:




Figure 2. A, waterfall plot of SUV change of target lesions after 2-day treatment of gefitinib ($n = 20$). *, this patient was excluded from later assessment because gefitinib was discontinued at 6 days. B, correlation between SUV change ($\Delta\text{SUV}\%$) at 2 days and CT size change ($\Delta\text{CTsize}\%$) at 1 month of target lesions ($n = 19$). C, agreement between metabolic response at 2 days on EORTC recommendations and morphologic overall response at 1 month on RECIST 1.0 ($n = 19$). $\kappa = 0.566$. EGFR mutation status is also shown. ND, not determined; NT, not tested; PR, partial response; SD, stable disease; PD, progressive disease; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease.

6 patients had an exon 19 deletion, 5 patients had an exon 21 L858R mutation, and one had an exon 18 G719S mutation. Median $\Delta\text{SUV}\%$ changes of target lesions in patients with mutated EGFR and wild-type EGFR were -29% and -2% , respectively (Fig. 2A). Of 12 patients with activating EGFR mutations, 8 (67%) were metabolic responders and 3 were with stable metabolic disease at 2 days, whereas 6 (50%) were morphologic responders and 5 were morphologically with stable disease at 1 month (Fig. 2C). Conversely, of 8 EGFR gene-assessable metabolic responders at 2 days, all had the activating mutations and 6 were assessed as morphologic responders at 1 month. Of 6 EGFR gene-assessable morphologic responders at 1 month, all had the mutations and were assessed as metabolic responders at 2 days. An 83-year-old female patient with an exon 19 deletion was assessed as having progressive metabolic disease while being with morphologically stable disease. During follow-up, this patient suffered from a relapse at 48 days. Another 79-year-old female patient with an exon 19 deletion was with stable metabolic disease at 2 days but assessed as having progressive disease because a new lesion appeared on PET/CT images at

1 month. All of 3 patients with wild-type EGFR were assessed with metabolically stable disease at 2 days. Two of these were assessed with morphologically stable disease and one had progressive disease at 1 month (Fig. 2C).

PFS according to metabolic and morphologic responses

When a cutoff value of -25% in $\Delta\text{SUV}\%$ was used between metabolic responders and nonresponders, PFS did not significantly correlate with metabolic response at 2 days. Median PFS of the responders and nonresponders was 290 days and 48 days, respectively (log-rank $P = 0.095$; Fig. 3A). This was attributable to a 58-year-old male nonresponder with an L858R mutation who was assessed with 21% decrease of $\Delta\text{SUV}\%$ and experienced the longest PFS of 680 days. When a cutoff value of -20% , which was still within the extent recommended by EORTC (22), was used, this patient was included in responders, and 2-day metabolic responders had significantly prolonged PFS compared with metabolic nonresponders (median, 296 vs. 42 days; $P < 0.0001$; Fig. 3B). When metabolic response was evaluated at 1 month, PFS was also significantly longer in




Figure 3. A, PFS of metabolic responders ($\Delta\text{SUV}\% < -25\%$) and nonresponders ($\Delta\text{SUV}\% \geq -25\%$) at 2 days. B, PFS of metabolic responders ($\Delta\text{SUV}\% < -20\%$) and nonresponders ($\Delta\text{SUV}\% \geq -20\%$) at 2 days. C, PFS of metabolic responders ($\Delta\text{SUV}\% < -25\%$) and nonresponders ($\Delta\text{SUV}\% \geq -25\%$) at 1 month. One patient did not have an FDG-PET scan at 1 month, without missing a CT scan. D, PFS of morphologic responders and nonresponders at 1 month. E, PFS according to a single PET activity at 2 days (SUV < 7 , black; SUV ≥ 7 , gray). *P* values were obtained using the log-rank test.

responders than in nonresponders even with the cutoff value of -25% (median, 302 vs. 42 days; $P < 0.0001$; Fig. 3C). Meanwhile, PFS did not correlate with morphologic response based on RECIST 1.0 even at 1 month of treatment (median, 296 vs. 48 days; $P = 0.100$; Fig. 3D) because the patient with the longest PFS of 680 days was assessed with stable disease. When this patient was excluded, 1-month morphologic response became significantly correlated with PFS ($P = 0.0003$).

In the clinical settings, SUV at baseline PET might be influenced by previous chemotherapy. Therefore, we also investigated whether an early metabolic assessment with a single post-gefitinib PET/CT scan would provide any useful

prognostic information. We defined an SUV threshold of 7, which was the nearest integer to the average SUV of the hottest target lesions in PET at 2 days, to separate responders (i.e., SUV < 7) from poor responders (SUV ≥ 7). There was a significant association between post-gefitinib FDG uptake and PFS (median, 244 days with SUV < 7 vs. 71 days with SUV ≥ 7 ; $P = 0.045$; Fig. 3E). Meanwhile, SUV in baseline PET studies was not predictive of PFS (median, 117 days with SUV < 10 vs. 93 days with SUV ≥ 10 ; $P = 0.611$).

In univariate analysis using the Cox hazards model, metabolic response using a cutoff value of -20% of $\Delta\text{SUV}\%$ at 2 days was the only predictive factor of PFS (HR = 0.04; $P < 0.0001$), other than *EGFR* mutation status (Table 2).

Table 2. Univariate analysis of predictive factors for PFS

Predictive factor	Analysis		
	<i>n</i>	HR (95% CI)	<i>P</i>
Age (≥ 70 y)	19	1.69 (0.60–4.58)	0.310
Sex (female)	19	1.19 (0.37–5.29)	0.789
Smoking history (never)	19	1.22 (0.39–5.46)	0.747
Metabolic response at 2 d ^a (yes)	19	0.04 (0.002–0.23)	< 0.0001
Morphologic response at 1 mo (yes)	19	0.44 (0.16–1.20)	0.109
<i>EGFR</i> mutation (yes)	15	0.17 (0.03–0.92)	0.041

^aA cutoff value of -20% in SUV decline was used.

In multivariate analysis including metabolic response at 2 days, morphologic response at 1 month, and smoking history, metabolic response at 2 days was the only statistically significant factor ($P = 0.0007$).

OS according to metabolic and morphologic responses

OS did not differ significantly between any metabolic responders and nonresponders and between the morphologic responders and nonresponders (Supplementary Fig. S1), although there was a trend for longer survival in metabolic responders who showed post-gefitinib SUV < 7 at 2 days ($P = 0.066$; Supplementary Fig. S1E).

Discussion

It has been evident that EGFR TKIs, gefitinib and erlotinib, induce dramatic responses in a subpopulation of patients with adenocarcinoma. Although the presence of somatic mutations in the *EGFR* gene is considered to be the best predictor of response to these TKIs (9, 10, 25, 26), its efficacy as biomarker is not satisfactory due to technical problems on biopsy, secondary mutation acquiring the resistance to the EGFR TKIs, and recent data showing response of patients with wild-type *EGFR* to erlotinib (27). Thus, an alternative approach optimizing clinical outcome of EGFR TKI therapy is necessary to accurately select patients who will benefit from the therapy and to avoid critical adverse effects such as interstitial lung disease (28).

Early response to therapy assessed by [¹⁸F]FDG-PET has been increasingly established as a prognostic biomarker in various malignancies (13). In NSCLC, two studies have just been published to show that early [¹⁸F]FDG-PET evaluation can predict PFS and OS in patients treated with erlotinib (29, 30). Another recent study reported that early [¹⁸F]FDG-PET predicted histopathologic response in patients with NSCLC treated with erlotinib as neoadjuvant therapy (31). Metabolic tumor responses were assessed 1 to 8 weeks after the start of erlotinib treatment in these studies. Meanwhile, Su and colleagues showed that gefitinib treatment induced rapid decreases of FDG uptake within 48 hours in sensitive tumors using a mouse model, providing a rationale for earlier assessment in clinical settings (16). In these sensitive tumors, glucose transporters rapidly translocated from the plasma membrane to the cytosol, and reduction of hexokinase activity was observed prior to changes in cell-cycle distribution, thymidine uptake, and apoptosis. Such changes were not found in an early decline of FDG uptake in response to conventional cytotoxic chemotherapy (32). A more recent study preliminarily analyzed 5 patients with advanced NSCLC and reported that, only 2 days after initiation of gefitinib therapy, SUV decreased by a mean of 61% in patients who showed partial response by conventional CT evaluation 4 weeks later (17).

Consistent with these studies, SUV decreased by up to a maximum of 52% at 2 days in the present prospective study, and we observed a strong correlation between changes in

SUV at 2 days and those in tumor size at 1 month. There was also a moderate agreement between metabolic responses at 2 days based on the EORTC recommendations and morphologic responses at 1 month according to RECIST 1.0. Moreover, metabolic response at 2 days could be a predictor of prolonged PFS when a cutoff value of -20% in SUV decline was used. The cutoff value of -25% , which was used in several other studies (33–35) but did not reach statistical significance in the present study, might be too large for the evaluation only after 2 days and for the sample size as small as 20. A single PET study at 2 days might also provide prognostic information. Patients with favorable response with lower post-gefitinib SUVs (SUV < 7) revealed longer PFS than poorly responding patients with higher SUVs (SUV ≥ 7), although significance was weak. There was a trend for an association between morphologic response at 1 month and improved PFS but it did not reach statistical significance, due to the presence of an *EGFR* mutation-positive patient showing stable disease but with a long PFS. In terms of OS, there was not significant difference, probably due to the small sample size and because OS is influenced by the second-line or later treatment. Together, although our study was a single-centered with a small number of patients, we propose that assessment of FDG uptake at 2 days could be a superior predictor of post-gefitinib outcome to conventional CT evaluation in its accuracy and rapidity.

Of 12 patients with activating *EGFR* mutations, 10 (83%) showed partial response or were with stable disease both in FDG-PET at 2 days and CT evaluation at 1 month. Thus, mutated *EGFR* is a good biomarker for response to gefitinib, as previously reported (6). Exceptionally, an 83-year-old female patient with exon 19 deletion had progressive metabolic disease at 2 days while being with morphologically stable disease at 1 month. She had a PFS of 48 days and this was relatively short for morphologically stable disease, the median PFS of which was 100 days. Another 79-year-old female patient with exon 19 deletion was with stable metabolic disease at 2 days while having morphologically progressive disease at 1 month. Her PFS was 30 days and relatively short for stable metabolic disease, the median PFS of which was 48 days. Thus, there was still inconsistency among *EGFR* mutations, early FDG-PET evaluation, or conventional CT evaluation, and larger prospective studies will be needed to clarify which is the best predictor of survival. Meanwhile, although it appears reasonable that none of 3 patients with wild-type *EGFR* showed metabolic or morphologic response, the number of patients is too small to discuss more about wild-type *EGFR*.

Interstitial lung disease is the most severe adverse effect, which occurs in approximately 1% of EGFR TKI-treated patients worldwide. Onset of symptoms may begin only after 2 days of gefitinib therapy. Median onset was 24 days in Japan and 42 days in United States, and about 1 of 3 of the cases were fatal (28). It has been suggested that [¹⁸F]FDG-PET may help to evaluate interstitial lung disease. Positive FDG uptake was observed in 86% of patients with idiopathic pulmonary fibrosis and correlated with disease

activity (36). In the present study, a 77-year-old male patient showed ground-glass opacity suggestive of interstitial infiltrate on chest radiograph, and gefitinib was discontinued at 6 days of treatment. At 2 days of treatment, his PET images did not show any positive uptake in lung parenchyma, and later on a CT scan, this infiltrate was rather considered a secondary change associated with obstructive bronchus. No other patient presented with interstitial infiltrate on chest radiograph. Thus, we could not determine at the moment whether [¹⁸F]FDG-PET can early detect gefitinib-induced lung damage.

In summary, early response assessment by FDG-PET could help to identify patients with lung adenocarcinoma who will benefit from gefitinib treatment. The present study showed promising data suggesting that clinical outcome can be predicted only after 2 days of the treatment. This early assessment may allow for rapid initiation of alternative strategies and minimize critical adverse effects such as interstitial lung disease when gefitinib is ineffective. The main limitation is the small sample size, and validation

with prospective studies in a larger patient population is warranted.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Y. Habe for secretarial assistance.

Grant Support

The work was supported by the grand-in-aid for community health and medical care from the Osaka University Medical School Alumni and the award from the Osaka Cancer Association. This trial is registered at www.umin.ac.jp/ctr/index/htm as UMIN000003621.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 14, 2011; revised October 6, 2011; accepted October 9, 2011; published OnlineFirst October 21, 2011.

References

- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer* 2007;7:169–81.
- Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol* 2003;21:2237–46.
- Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290:2149–58.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123–32.
- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366:1527–37.
- Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene* 2009;28 Suppl 1:S24–31.
- Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. *Oncogene* 2009;28 Suppl 1:S32–7.
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–57.
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380–8.
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121–8.
- John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. *Oncogene* 2009;28 Suppl 1:S14–23.
- Burris HA III. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. *Oncogene* 2009;28 Suppl 1:S4–13.
- Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. *Lancet Oncol* 2004;5:531–40.
- Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). *Eur J Cancer* 2003;39:2012–20.
- Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. *Nucl Med Commun* 2004;25:433–8.
- Su H, Bodenstein C, Dumont RA, Seimbielle Y, Dubinett S, Phelps ME, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. *Clin Cancer Res* 2006;12:5659–67.
- Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. *Lung Cancer* 2008;59:203–10.
- Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. *Cancer Res* 2005;65:7276–82.
- Inohara H, Enomoto K, Tomiyama Y, Higuchi I, Inoue T, Hatazawa J. Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma. *Mol Imaging Biol* 2010;12:89–97.
- Therasse P, Arbuuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205–16.
- Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. *J Nucl Med* 2004;45:357–65.
- Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [¹⁸F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. *Eur J Cancer* 1999;35:1773–82.

23. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. *APMIS* 1989;97:689–98.
24. Lee ET, Go OT. Survival analysis in public health research. *Annu Rev Public Health* 1997;18:105–34.
25. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497–500.
26. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
27. Cappuzzo F, Ciuleanu T, Stelmakh L, Ciceanu S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2010;11:521–9.
28. Cersosimo RJ. Gefitinib: an adverse effects profile. *Expert Opin Drug Saf* 2006;5:469–79.
29. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. *J Clin Oncol* 2011;29:1701–8.
30. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. *Clin Cancer Res* 2011; 17:3304–15.
31. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? *J Nucl Med* 2010;51:1344–8.
32. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. *J Nucl Med* 1998;39:1757–62.
33. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. *Eur J Nucl Med Mol Imaging* 2005;32:153–62.
34. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. *J Clin Oncol* 2009;27:439–45.
35. Lee DH, Kim SK, Lee HY, Lee SY, Park SH, Kim HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. *J Thorac Oncol* 2009;4:816–21.
36. Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. *Respiration* 2006;73:197–202.

Clinical Cancer Research

Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

Ryo Takahashi, Haruhiko Hirata, Isao Tachibana, et al.

Clin Cancer Res 2012;18:220-228. Published OnlineFirst October 21, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-11-0868](https://doi.org/10.1158/1078-0432.CCR-11-0868)

Supplementary Material Access the most recent supplemental material at:
<http://clincancerres.aacrjournals.org/content/suppl/2011/10/21/1078-0432.CCR-11-0868.DC1>

Cited articles This article cites 36 articles, 10 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/18/1/220.full#ref-list-1>

Citing articles This article has been cited by 16 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/18/1/220.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/18/1/220>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.